Application of the MRC brain tumour prognostic index to patients with malignant glioma not managed in randomised control trial

Journal of Neurology Neurosurgery and Psychiatry

Volumn 64, Issue 6, 1998, Pages 747-750

  Latif, Abdullah Z B ^a   Signorini, David ^a   Gregor, Anna ^a   Grant, Robin ^a   Ironside, James W ^a   Whittle, Ian R ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Glioma radiotherapy; Prognostic index

Indexed keywords

ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL; SURVIVAL TIME;

EID: 0031800640     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.64.6.747     Document Type: Article

References (16)

1. Fine HA. The Basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994;20:111-20.
2. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 1989;71:1-9.
3. A report from the MRC Working Pary on Misonidazole in Gliomas. A study of the effect of misonidazole in conjunction with radiotherapy for the treatment of grades 3 and 4 astrocytomas. Br J Radiol 1983;56:673-82.
4. Simpson J R, Horton J, Scott C, et al. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme; results from three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys 1993;26:239-44.
5. MRC Brain Tumour Working Party. Prognostic factors for high grade gliomas: development of a prognostic index. J Neurooncol 1990;9:47-55.
6. Grant R, Whittle IR, Collie DA, et al. Referral pattern and mix of patients with malignant brain tumours in SE Scotland. Health Bull (Edinb) 1996;54:212-22.
7. Whittle IR. The management of malignant glioma. J Neurol Neurosurg Psychiatry 1996;72:3-6.
8. Burger PC, Vogel FC, Green SB, et al. Glioblastoma and anaplastic astrocytoma; pathological criteria and prognostic implications. Cancer 1985;56:1106-11.
9. Nelson J S, Tsukada Y, Schoenfeld D, et al. Necrosis as a prognostic criterion in malignant supratentorial astrocytic gliomas. Cancer 1983;52:550-2.
10. Selby R. The surgical treatment of cerebral glioblastoma multiformeran historical review. J Neurooncology 1994;18: 175-82.
11. Bleehan NM, Stenning SP on behalf of the Medical Research Council Brain Tumour Working Party. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. Br J Cancer 1991; 64:769-74.
12. Tibshirani R. A plain man's guide to the proportional hazards model. Clin Invest Med 1982;5:63-8.
13. Grambsch PM, Therneau TM. Proportional hazards tests and the diagnostics based on weighted residuals. Biometrika 1994;81:515-26.
14. Gregor A, Rampling R, Aapro M, et al. Phase II study of tauromustine in malignant glioma. Eur J Cancer 1992;28: 1959-62.
15. Whittle IR, MacPherson JS, Miller JD, et al. The disposition of TCNU (tauromustine) in human malignant glioma; pharmacokinetic studies and clinical implications. J Neurosurg 1990;72:721-5.
16. Stenning SP, Freedman LS, Bleehen NM. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 1987; 56:89-90.